Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Frontiers of Radiation Therapy and Oncology|December 4, 2009
Radiation therapy for early stage (I/II) non-small cell lung cancerBranislav Jeremic, Francesc Casas, Luhua Wang, et al.
Frontiers of Radiation Therapy and Oncology|December 4, 2009
Radiochemotherapy in extensive disease small cell lung cancer ED-SCLCBranislav Jeremic, Francesc Casas, Luhua Wang, et al.
Medicina Clinica|July 2, 2005
[Impact of age and comorbidity on survival and toxicity of irradiated prostate cancer patients]Ferran Ferrer González, Francesc Casas Duran, Albert Biete Solà
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|December 31, 2013
Whole abdominal radiotherapy in ovarian cancerAlberto Biete, Izaskun Valduvieco, Angels Rovirosa, et al.
Clinical Lung Cancer|December 20, 2015
Surgery for Stage IIIA Non-Small-cell Lung Cancer: Lack of Predictive and Prognostic Factors Identifying Any Subgroup of Patients Benefiting From ItBranislav Jeremić, Francesc Casas, Pavol Dubinsky, et al.
Expert Review of Anticancer Therapy|October 16, 2009
Combination of radiotherapy and chemotherapy in locally advanced NSCLCLucyna Kepka, Arkadiusz Sprawka, Francesc Casas, et al.
Expert Review of Anticancer Therapy|October 16, 2009
Radiochemotherapy in small-cell lung cancerLucyna Kepka, Arkadiusz Sprawka, Francesc Casas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 22, 2023
Biological equivalent dose is associated with radiological toxicity after lung stereotactic ablative radiation therapyCarla Cases, Mariana Benegas, Marcelo Sánchez, et al.
Journal of Radiation Research|March 25, 2017
Combined modality therapy in Stage IIIA non-small cell lung cancer: clarity or confusion despite the highest level of evidence?Branislav Jeremic, Francesc Casas, Pavol Dubinsky, et al.
Frontiers in Oncology|March 13, 2018
Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung CancerBranislav Jeremić, Francesc Casas, Pavol Dubinsky, et al.
Pageof 4